APLP2 regulates the expression of MHC class I molecules on irradiated Ewing's sarcoma cells.

ABSTRACT: Ewing's sarcoma (EWS) is a pediatric cancer that is conventionally treated by surgery, chemotherapy, and radiation therapy. Innovative immunotherapies to treat EWS are currently under development. Unfortunately for EWS patients, when the disease is found to be resistant to current therapeutic approaches, the prognosis is predictably grim. Radiation therapy and immunotherapy could potentially synergize in the eradication of EWS, as some studies have previously shown that irradiation increases the presence of immune receptors, including MHC class I molecules, on the surface of tumor cells. However, EWS cells have been reported to express low levels of MHC class I molecules, a phenotype that would inhibit T-cell mediated lysis. We have previously demonstrated that the transgene-driven overexp

SUBMITTER: Peters HL 

PROVIDER: S-EPMC3862638 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature